公开(公告)号：US20240082240A1

公开(公告)日：2024-03-14

申请号：US18385686

申请日：2023-10-31

Applicant: NOVMETAPHARMA CO, LTD.

Inventor： In-Kyu LEE ,  Jae-Han JEON ,  Dipanjan CHANDA ,  Eun Jung CHOI ,  Hoe Yune JUNG ,  Heon Jong LEE

IPC: A61K31/495

CPC classification number: A61K31/495

Abstract: A composition for preventing and/or treating cytokine release syndrome and a method of prevention and/or treatment of cytokine release syndrome are disclosed. The composition includes an aryl ethene compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, as an active ingredient. The method includes administering the aryl ethene compound, an isomer, a pharmaceutically acceptable salt thereof, or a solvate thereof, in an effective amount to a subject in need thereof. The cytokine release syndrome may be caused by virulent infection. The administration of the compound reduces the pre-inflammatory cytokine levels in the subject.

公开(公告)号：US20190175583A1

公开(公告)日：2019-06-13

申请号：US16324784

申请日：2017-08-14

Applicant: NOVMETAPHARMA CO., LTD. ,  Postech Academy-Industry Foundation

Inventor： Kyong Tai KIM ,  Hoe Yune JUNG ,  Heon Jong LEE

IPC: A61K31/4706 ,  A61K45/06 ,  A61P3/10 ,  A61P3/04 ,  A61P3/06 ,  A61P1/16 ,  A61P9/00

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating diabetes, and controlling a side effect from peroxisome proliferator-activated receptor-gamma (PPAR-gamma) activation, wherein the pharmaceutical composition comprises (a) an amodiaquine compound or a pharmaceutically acceptable salt thereof and (b) an antidiabetic drug as active ingredients. Specifically, the composition prevents or treats simultaneously one or more selected from the group consisting of type 2 diabetes reactive to PPAR-gamma activation, and obesity, dyslipidemia, cardiovascular diseases, and fatty cirrhosis reactive to peroxisome proliferator-activated receptor-alpha (PPAR-alpha) activation.

公开(公告)号：US20240261366A1

公开(公告)日：2024-08-08

申请号：US18427249

申请日：2024-01-30

Applicant: NOVMETAPHARMA CO., LTD. ,  KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Hail KIM ,  Hoeyune JUNG ,  Kyun Hoo KIM ,  Joonyub LEE ,  Hyeonkyu LEE ,  Heon Jong LEE

IPC: A61K38/12 ,  A61K33/30 ,  A61K45/06 ,  A61P1/18

CPC classification number: A61K38/12 ,  A61K33/30 ,  A61K45/06 ,  A61P1/18

Abstract: A method and composition for treating and/or preventing β-cell dysfunction and/or protecting impaired β-cells are disclosed. The method includes administering an effective amount of cyclo (his-pro) (CHP), alone or with zinc, to a subject. The composition contains an effective amount of cyclo (his-pro) (CHP) as an active ingredient. The composition may further contain zinc and/or other antidiabetic agent, or can be administered in combination with zinc and/or other antidiabetic agent.

公开(公告)号：US20220202897A1

公开(公告)日：2022-06-30

申请号：US17599211

申请日：2020-03-30

Applicant: NOVMETAPHARMA CO., LTD. ,  SEOUL NATIONAL UNIVERSITY HOSPITAL ,  SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION

Inventor： Hoe Yune JUNG ,  Heon Jong LEE ,  Jong Su JEON ,  Do Hyun LEE ,  Yon Su KIM ,  Seung Hee YANG ,  Yong Chul KIM ,  Jong Joo MOON ,  Ji Eun KIM

IPC: A61K38/12 ,  A61P19/04 ,  A61P11/00 ,  A61P1/16

Abstract: A Cyclo (his-pro) (CHP) is useful for preventing, ameliorating, or treating fibrosis. A pharmaceutical composition containing CHP may be used for preventing or treating fibrosis. A health functional food composition containing CHP may be used for preventing or ameliorating fibrosis. An antifibrotic composition, a method of preventing, ameliorating, or treating fibrosis by using CHP, and/or a use of CHP in the manufacture of the pharmaceutical composition for preventing or treating fibrosis are disclosed.

公开(公告)号：US20220193179A1

公开(公告)日：2022-06-23

申请号：US17599118

申请日：2020-03-30

Applicant: NOVMETAPHARMA CO., LTD. ,  SEOUL NATIONAL UNIVERSITY HOSPITAL ,  SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION

Inventor： Hoe Yune JUNG ,  Do Hyun LEE ,  Heon Jong LEE ,  Yon Su KIM ,  Seung Hee YANG

IPC: A61K38/01 ,  A61P43/00 ,  A23L33/18

Abstract: A cyclo(His-Pro)(CHP) is useful for preventing, alleviating or treating peritoneal fibrosis. A pharmaceutical composition for preventing or treating peritoneal fibrosis, a dietary supplement composition for preventing or alleviating peritoneal fibrosis, and a peritoneal dialysis solution, which all contain CHP is disclosed. Also disclosed are a method for preventing or treating peritoneal fibrosis by using CHP, a peritoneal dialysis method using CHP, a use of CHP during the preparation of a pharmaceutical composition for preventing or treating peritoneal fibrosis, and/or a use of CHP in the preparation of a peritoneal dialysis solution.

公开(公告)号：US20240140955A1

公开(公告)日：2024-05-02

申请号：US18476630

申请日：2023-09-28

Applicant: NOVMETAPHARMA CO., LTD.

Inventor： Heon Jong LEE ,  Hoe Yune JUNG

IPC: C07D487/06

CPC classification number: C07D487/06

Abstract: Novel PEG modified cyclic dipeptide compounds are disclosed. The modified cyclic dipeptide compounds contain a cyclic dipeptide and a biocompatible polymer attached to the cyclic dipeptide. The cyclic dipeptide may be proline-containing, hydroxyproline-, or histidine-containing cyclic dipeptide. In one embodiment, the cyclic dipeptide is a cyclo (-his-pro). Exemplary modified cyclic dipeptide compounds are represented by Formula A′:

公开(公告)号：US20230165855A1

公开(公告)日：2023-06-01

申请号：US17912942

申请日：2021-03-19

Applicant: NOVMETAPHARMA CO., LTD. ,  SEOUL NATIONAL UNIVERSITY HOSPITAL ,  SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION

Inventor： Hoe Yune JUNG ,  Heon Jong LEE ,  Yon Su KIM ,  Seung Hee YANG

IPC: A61K31/4985 ,  A61P9/12

CPC classification number: A61K31/4985 ,  A61P9/12

Abstract: New uses of Cyclo-HisPro (CHP) or a salt thereof for lowering blood pressure are disclosed. More specifically, the present invention relates to a pharmaceutical composition for lowering blood pressure, containing CHP or a salt thereof, and a functional health food composition containing CHP or a salt thereof; a method for lowering blood pressure using CHP or a salt thereof; a use of CHP or a salt thereof in the manufacture of antihypertensive agents; a pharmaceutical composition or a functional health food, for preventing or treating hypertension or complications thereof, containing CHP or a salt thereof; a method for preventing or treating hypertension or complications thereof by using CHP or a salt thereof; and a use of CHP or a salt thereof in the manufacture of a medicament for preventing or treating hypertension or complications thereof.

公开(公告)号：US20220218793A1

公开(公告)日：2022-07-14

申请号：US17612038

申请日：2020-05-18

Applicant: NOVMETAPHARMA CO., LTD.

Inventor： Hoe Yune JUNG ,  Do Hyun LEE ,  Heon Jong LEE

IPC: A61K38/29 ,  A61P19/10

Abstract: A use of a cyclo(his-pro) (CHP) in combination with parathyroid hormone (PTH) and compositions containing the CHP in combination with PTH is disclosed. The combination of CHP and PTH is useful for preventing, improving, or treating a bone loss-related disease. Therefore, a method for treating, preventing, or improving bone loss-related disease in a subject, which includes administering the CHP in combination with PTH is disclosed. The PTH and CHP may be administered to the subject simultaneously, separately, or sequentially.

公开(公告)号：US20250161301A1

公开(公告)日：2025-05-22

申请号：US18954719

申请日：2024-11-21

Applicant: NOVMETAPHARMA CO., LTD

Inventor： Hoe Yune JUNG ,  Jongsu JEON ,  Do Hyun LEE ,  Seo Yeong BAEK ,  Shin Yu BAEK ,  Heon Jong LEE

IPC: A61K31/4985 ,  A61K33/30 ,  A61P3/04 ,  A61P3/10

Abstract: A composition for preventing, ameliorating or treating obesity and diabetes and its uses are disclosed. The composition includes zinc gluconate and cyclo-hispro (CHP) as active ingredients. More specifically, the composition includes the type of zinc salts and/or the content ratio of zinc components optimized for surprisingly significantly improved anti-obesity and anti-diabetic effects. A method of preventing, ameliorating or treating obesity and diabetes using the composition is also disclosed.

公开(公告)号：US20220362269A1

公开(公告)日：2022-11-17

申请号：US17852774

申请日：2022-06-29

Applicant: NovMetaPharma Co., Ltd.

Inventor： Heon Jong LEE ,  Heo Yune Jung ,  In-Kyu Lee ,  Jae-Han Jeon ,  Sung Jin Cho ,  Jina Kim ,  Hayoung Hwang ,  Yong Hyun Jeon ,  Jungwook Chin

IPC: A61K31/695 ,  A61K31/495 ,  A61K31/4453 ,  A61K31/5375 ,  A61K31/40 ,  A61K31/396 ,  A61K31/397 ,  A61K31/454 ,  A61K31/4025 ,  A61K31/407 ,  A61K31/443 ,  A61K31/403 ,  A61K31/433 ,  A61P1/18

Abstract: A composition for preventing and/or treating pancreatitis and a method of prevention and/or treatment of pancreatitis are disclosed. The composition include an aryl ethene compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, as an active ingredient. Also disclosed is a use of the aryl ethene compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, in manufacturing a medicament for preventing and/or treating pancreatitis or for treating one or more symptoms of pancreatitis in a patient. The method of prevention and/or treatment of pancreatitis includes administering the aryl ethene compound, an isomer, a pharmaceutically acceptable salt thereof, or a solvate thereof, in an effective amount to a subject in need thereof.